Last reviewed · How we verify
batch 3 of Ad5-nCoV
Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.
Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention.
At a glance
| Generic name | batch 3 of Ad5-nCoV |
|---|---|
| Also known as | Convidecia |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine uses a replication-deficient adenovirus serotype 5 as a viral vector to introduce genetic material encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, including T-cell and antibody production against the spike protein, providing protection against COVID-19 infection and severe disease.
Approved indications
- COVID-19 prevention
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- batch 3 of Ad5-nCoV CI brief — competitive landscape report
- batch 3 of Ad5-nCoV updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI